Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Croucher

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
The Journal of Biological Chemistry|May 25, 2011
Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancerBlake J Cochran, David R Croucher, Sergei Lobov, et al.
Brain Research|March 29, 2014
t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditionsRoxann Freeman, Be'eri Niego, David R Croucher, et al.
Molecular and Cellular Biology|September 1, 2010
Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cellsDavid R Croucher, Danny Rickwood, Carole M Tactacan, et al.
The FEBS Journal|February 21, 2012
Signalling by protein phosphatases and drug development: a systems-centred viewLan K Nguyen, David Matallanas, David R Croucher, et al.
British Journal of Pharmacology|March 7, 2018
The extracellular matrix as a key regulator of intracellular signalling networksJordan F Hastings, Joanna N Skhinas, Dirk Fey, et al.
Frontiers in Cell and Developmental Biology|October 29, 2020
Histone Deacetylases and Histone Deacetylase Inhibitors in NeuroblastomaMonica Phimmachanh, Jeremy Z R Han, Yolande E I O'Donnell, et al.
Journal of Personalized Medicine|June 2, 2021
Personalized Medicine for Neuroblastoma: Moving from Static Genotypes to Dynamic Simulations of Drug ResponseJeremy Z R Han, Jordan F Hastings, Monica Phimmachanh, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 20, 2021
In Vitro 3D Models of Tunable StiffnessElysse C Filipe, Amelia L Parker, Antonia L Cadell, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2020
A cryptic tubulin-binding domain links MEKK1 to curved tubulin protomersPavel Filipčík, Sharissa L Latham, Antonia L Cadell, et al.
Molecular Cancer Therapeutics|January 24, 2007
Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinomaTamantha K Stutchbury, Fares Al-Ejeh, Gillian E Stillfried, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
The Journal of Biological Chemistry|May 25, 2011
Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancerBlake J Cochran, David R Croucher, Sergei Lobov, et al.
Brain Research|March 29, 2014
t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditionsRoxann Freeman, Be'eri Niego, David R Croucher, et al.
Molecular and Cellular Biology|September 1, 2010
Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cellsDavid R Croucher, Danny Rickwood, Carole M Tactacan, et al.
The FEBS Journal|February 21, 2012
Signalling by protein phosphatases and drug development: a systems-centred viewLan K Nguyen, David Matallanas, David R Croucher, et al.
British Journal of Pharmacology|March 7, 2018
The extracellular matrix as a key regulator of intracellular signalling networksJordan F Hastings, Joanna N Skhinas, Dirk Fey, et al.
Frontiers in Cell and Developmental Biology|October 29, 2020
Histone Deacetylases and Histone Deacetylase Inhibitors in NeuroblastomaMonica Phimmachanh, Jeremy Z R Han, Yolande E I O'Donnell, et al.
Journal of Personalized Medicine|June 2, 2021
Personalized Medicine for Neuroblastoma: Moving from Static Genotypes to Dynamic Simulations of Drug ResponseJeremy Z R Han, Jordan F Hastings, Monica Phimmachanh, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 20, 2021
In Vitro 3D Models of Tunable StiffnessElysse C Filipe, Amelia L Parker, Antonia L Cadell, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2020
A cryptic tubulin-binding domain links MEKK1 to curved tubulin protomersPavel Filipčík, Sharissa L Latham, Antonia L Cadell, et al.
Molecular Cancer Therapeutics|January 24, 2007
Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinomaTamantha K Stutchbury, Fares Al-Ejeh, Gillian E Stillfried, et al.
Pageof 6